ReviewFrontiers in endocrinology2019
Braving the Element: Pancreatic β-Cell Dysfunction and Adaptation in Response to Arsenic Exposure.
Review in Frontiers in endocrinology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Global Analysis of Metabolic Fluxes of Glucose and Glutamine in INS‑1 Cells Exposed to Arsenite UsingEnvironment & health (Washington, D.C.) · 2026Article
- Occupational heavy metal exposure and endocrine-metabolic biomarkers: a retrospective analysis of 34,595 screened individuals in Türkiye.BMC endocrine disorders · 2026Article
- Association of Urine Heavy Metals with Prevalence of Type 1 Diabetes and Poor Glycaemic Control.Biological trace element research · 2026Article
- Glucose shields RINm5F beta cells against arsenic-induced apoptosis.Scientific reports · 2025Article
- Consensus on the key characteristics of metabolism disruptors.Nature reviews. Endocrinology · 2025Review
- Arsenic exposure during pregnancy and postpartum maternal glucose tolerance: evidence from Bangladesh.Environmental health : a global access science source · 2022Article
- Is Arsenic Exposure a Risk Factor for Metabolic Syndrome? A Review of the Potential Mechanisms.Frontiers in endocrinology · 2022Review
- Article
- Arsenic Exposure, Arsenic Metabolism, and Glycemia: Results from a Clinical Population in New York City.International journal of environmental research and public health · 2021Article
- Arsenic Exposure Decreases Adiposity During High-Fat Feeding.Obesity (Silver Spring, Md.) · 2020Article
- Subacute Testicular Toxicity to Cadmium Exposure Intraperitoneally and Orally.Oxidative medicine and cellular longevity · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes mellitus (T2DM) is a serious global health problem, currently affecting an estimated 451 million people worldwide. T2DM is characterized by hyperglycemia and low insulin relative to the metabolic demand. The precise contributing factors for a given individual vary, but generally include a combination of insulin resistance and insufficient insulin secretion. Ultimately, the progression to diabetes occurs only after β-cells fail to meet the needs of the individual. The stresses placed upon β-cells in this context manifest as increased oxidative damage, local inflammation, and ER stress, often inciting a destructive spiral of β-cell death, increased metabolic stress due to further insufficiency, and additional β-cell death. Several pathways controlling insulin resistance and β-cell adaptation/survival are affected by a class of exogenous bioactive compounds deemed endocrine disrupting chemicals (EDCs). Epidemiological studies have shown that, in several regions throughout the world, exposure to the EDC inorganic arsenic (iAs) correlates significantly with T2DM. It has been proposed that a lifetime of exposure to iAs may exacerbate problems with both insulin sensitivity as well as β-cell function/survival, promoting the development of T2DM. This review focuses on the mechanisms of iAs action as they relate to known adaptive and maladaptive pathways in pancreatic β-cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.